Patient Medication Instructions: How should you take trametinib?

Trametinib (Trametinib) is an orally bioavailable inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It was first approved by the U.S. Food and Drug Administration (FDA) in May 2013 for the treatment of melanoma. Trametinib is currently approved to treat a variety of BRAF-mutated cancers, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with dabrafenib, a BRAF inhibitor.

Before initiating monotherapy or combination therapy, an FDA-approved in vitro diagnostic test (such as a BRAF kit) is required to confirm the presence of the BRAF V600E or V600K mutation. Trametinib mainly exists in the form of tablets. For adult patients, the recommended dose is 2 mg; for pediatric patients, the dosage is related to body weight: the recommended dose for pediatric patients weighing 26-37 kg is 1 mg orally once a day; for pediatric patients weighing 38-50 kg, the recommended dose is 1.5 mg orally once a day; for patients weighing 51 kg or above, the recommended dose is 2 mg orally once a day; for patients weighing less than 26 kg, the recommended dose has not yet been determined.

When taking trametinib, patients need to follow some important medication instructions to maximize efficacy and reduce side effects. First of all, it is recommended that patients take trametinib at the same time every day to ensure stable blood concentration. The medication time should be set at least 1 hour before meals or 2 hours after meals to avoid the impact of food on drug absorption. In addition, if patients accidentally miss a dose while taking the drug, they should avoid taking the untaken dose within 12 hours before the next dose to avoid a sudden increase in drug concentration and adverse reactions.